SG Americas Securities LLC Has $106.45 Million Stake in Becton, Dickinson and Company $BDX

SG Americas Securities LLC reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.3% during the 1st quarter, HoldingsChannel reports. The fund owned 677,017 shares of the medical instruments supplier’s stock after selling 53,037 shares during the quarter. SG Americas Securities LLC’s holdings in Becton, Dickinson and Company were worth $106,447,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BDX. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Graybill Wealth Management LTD. boosted its position in Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock worth $5,164,000 after acquiring an additional 8,859 shares during the last quarter. Skba Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 1,619.9% during the 3rd quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after acquiring an additional 54,170 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $34,596,000. Finally, Elo Mutual Pension Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 24.7% in the third quarter. Elo Mutual Pension Insurance Co now owns 34,609 shares of the medical instruments supplier’s stock valued at $6,478,000 after purchasing an additional 6,856 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the sale, the executive vice president directly owned 14,272 shares in the company, valued at $2,161,922.56. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,013 shares of company stock worth $593,434 over the last three months. Insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Barclays boosted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Bank of America dropped their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Finally, Evercore lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $181.00.

Becton, Dickinson and Company Stock Performance

BDX opened at $143.99 on Monday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The business has a 50 day moving average of $148.89 and a 200-day moving average of $172.17. The stock has a market cap of $39.67 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 10.19 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.